Sign Up to like & get recommendations! 0
Published in 2020 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-020-00985-5
Abstract: We read with interest the cost-effectiveness study by Narasimhalu et al. [1], which evaluated the cost effectiveness of CYP2C19 genotype-guided antiplatelet therapy in an Asian population of patients presenting with acute ischaemic stroke with the… read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "Renal Failure"
DOI: 10.1080/0886022x.2025.2523567
Abstract: Abstract Genetic polymorphisms in CYP3A5 affects tacrolimus (Tac) bioavailability; however the optimal genotype-guided starting dose remains undefined. This retrospective cohort study examined the effects of the CYP3A5 allele on Tac pharmacokinetics in 431 Taiwanese renal… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Biomarkers"
DOI: 10.1080/1354750x.2019.1634764
Abstract: Abstract To evaluate whether genotype-guided antiplatelet therapy reduces the rates of cardiovascular events and bleeding events in patients with acute coronary syndrome (ACS). We systematically searched Pubmed, Embase and the Cochrane Central Register of Controlled… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13621
Abstract: Previous trials on the effectiveness of genotype‐guided warfarin dosing vs. conventional dosing have been inconclusive. We conducted a systematic review and meta‐analysis of randomized trials comparing genotype‐guided to conventional dosing strategies. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.18165
Abstract: 1966; 34: 827–857 PMID:5330347. 7 Insee. A Mayotte, pr es d’un habitant sur deux est de nationalit e etrang ere. Montrouge, Paris: Insee Premi ere. 2019;1737 [Internet]. French. https:// www.insee.fr/fr/statistiques/3713016 (last accessed 16 November 2021).… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.423
Abstract: 423Background: 5-FU, IRI, and nab-paclitaxel (NP) are active in advanced GI cancers; the combination (FOLFIRABRAX) has not been evaluated. UGT1A1 clears SN-38, the active metabolite of IRI. UGT1A1*28 polymorphism reduces enzymatic activity and predisposes to… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3574
Abstract: 3574Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA repeats) and UGT1A1*93 (SNP -3156G > A) are significantl... read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cardiovascular Diagnosis and Therapy"
DOI: 10.21037/cdt-22-154
Abstract: Background The implementation of genotyping for anti-hypertensive drugs in clinical practice remains a challenge. We conducted this study to analyze the distribution of polymorphisms of antihypertensive drug-related genes in Changsha County in China and compare… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.850028
Abstract: The pharmacodynamics of the purinergic receptor type Y, subtype 12 (P2Y12) inhibitors has evolved. Our understanding of the metabolism of P2Y12 inhibitors has revealed polymorphisms that impact drug metabolism and antiplatelet efficacy, leading to genetic… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.854519
Abstract: Background Clarithromycin resistance reduces the eradication rate of Helicobacter pylori (H. pylori). Cultures with susceptibility testing and molecular determination of genotypes are recommended to guide-tailored therapy. Methods We retrospectively enrolled patients aged 6 and 18… read more here.